TMC-310911
TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that has been investigated for use in HIV-1 infections and is structurally similar to the darunavir. TMC-310911 has demonstrated potential activity against a number of HIV-1 strains, including multi-PI-resistant strains, and may be less likely to produce resistance, making it a potentially suitable therapy for patients who are both native to care and experienced with PI. The Hangzhou-based Ascletis Pharma, applied to the Chinese authorities in January to study Ritonavir and TMC-310911 (two HIV protease inhibitor) in clinical trials for treatment of COVID-19. TMC-310911 as a possible therapy for COVID-19 caused by SARS-CoV-2 in conjunction with other HIV therapies and antivirals.TMC-310911 is currently being investigated, in combination with other HIV therapies and antivirals, as a potential treatment for 2019-nCoV [41][42].